Podcasts about groups

Send us a textIn Part One, organizational behavior scholar Colin M. Fisher dismantles the myth of the lone genius, showing that performance is shaped less by individual talent and more by the groups people belong to. He reframes leadership around social norms, group dynamics, and collective context—arguing that leaders often misdiagnose performance problems by focusing on people instead of the group system they operate within.Part Two builds on that foundation with practical guidance for leaders. Fisher explains why teams frequently underperform—not because of effort or ability, but because organizations are designed to reward and manage individuals, not collective work. He introduces the concept of relaunching teams, offering a roadmap for resetting goals, norms, and roles so groups can move from friction to true collaboration. The episode closes with a powerful shift in perspective: sustainable performance improves when leaders stop fixing individuals and start strengthening the group.Episode Highlights• Why teams often perform worse than individuals—and how leaders can     change that.• The 60–30–10 rule that explains what really drives team performance• How to relaunch a struggling or inherited team• The role of shared goals, norms, and “superpowers” in building trust• Moving from me vs. you to us vs. the problemGuest:  Colin M. Fisher, Ph.D. author of the book,The Collective Edge: Unlocking the Secret Power of Groups Host, Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of Leadership.The Anatomy of Leadership podcast explores the art and science of leadership through candid, insightful conversations with thought leaders, innovators, and change-makers from a variety of industries. Hosted by Chris Comeaux, each episode dives into the mindsets, habits, and strategies that empower leaders to thrive in complex, fast-changing environments. With topics ranging from organizational culture and emotional intelligence to navigating disruption and inspiring teams, the show blends real-world stories with practical takeaways. The goal is simple yet ambitious: to equip leaders at every level with the tools, perspectives, and inspiration they need to lead with vision, empathy, and impact. https://www.teleioscn.org/anatomy-of-leadership

Episode 108 – BTG Listener-Favorite Series: A past conversation with pastor, author, and podcaster Havilah Cunnington and our podcast host, Mykelti Blum. In this episode, they discuss boundaries and some of Havilah's journey in understanding what boundaries meant for her. She shares practical tools and insight into how to incorporate boundaries within friendships, careers, and self care. Whether you’re newer to the podcast or have been listening for a while, our hope is that you will be encouraged in a fresh way by this past conversation, as it contains rich biblical wisdom and practical application for your life today! Learn more about Havilah and find resources, including her book I Do Boundaries at havilahcunnington.com. Follow @MNBTG on Instagram, Facebook, and YouTube. Subscribe to the BTG Podcast on Apple Podcasts, iHeart, Spotify, YouTube, or listen on WordPress. BTG Events & Resources: 2026 BTG Leadership Conference February 20-21 Lake Geneva Christian Center (Alexandria, MN) Featuring Kristie Kerr and Keaton & Emily Goetz (worship) Main Sessions (including the Lund Leadership Award Presentation and the Leadership Exchange), Workshops, the After-Party, Exhibitor Shopping, Networking, and More!  Early Bird Deadline: January 31 Register: mnbtg.org/leadership. 2026 Single Moms Retreat  May 29-30, 2026 Lake Geneva Christian Center (Alexandria, MN) Featured Guests: Brooke Maxwell, Kevin Ramsby, and Amber Gerstmann (emcee) Main Sessions, Multiple Workshops, Lots of INCLUDED Activities and Giveaways. Learn More & Register to Attend, Exhibit, or Volunteer: mnbtg.org/retreat. 2026 Garden Coffee Free Missional Event for Women and Girls of All Ages! July 3, 2026, at Lake Geneva Christian Center in Alexandria, MN. Enjoy Refreshments, Worship Together, and Hear from a MN Global Worker. You’ll Also Have the Opportunity to Invest Into Missions (to Support Our 1000 Sisters Fund). Learn More at mnbtg.org/1000sisters. No RSVP Required; Invite Your Family and Church Community! 2026 Thrive Conference October 9-10, 2026 Mayo Civic Center (Rochester, MN) Featuring Lisa Bevere, Christina Girma-Hanfere, Martha Tennison, Susie Larson (speaker and emcee), & Amber Gerstmann (emcee) Afternoon & Main Sessions, “LIVE at Thrive with Susie Larson” — a BTG Podcast Recording Experience, Lunch with Speakers, the Thrive After-Party, Shopping, and More! Groups of 40 or More Who Register by September 20 Will Receive Reserved Seating. See All Ticket Types, and Register: First-Time Guests to Thrive in Rochester Can Register for ONLY $20 FREE Tickets for 2026 High School Grads and North Central University and Trinity Bible College and Graduate School undergrad students! Email info@mnbtg.org to Request Your Coupon Code. (These free tickets are not transferrable.) BTG Missions Trips and Giving Opportunity Learn About Our 2025-2026 BTG Missions Partners, and Give A Tax-Deductible Gift Toward Our $500,000 Goal: mnbtg.org/missions. Apply to join a 2026 BTG Missions Trip to Prague or Budapest: mnbtg.org/trips. Please take a moment to rate and review the podcast to help others find this resource, as well!

In Part One, organizational behavior scholar Colin M. Fisher dismantles the myth of the lone genius, showing that performance is shaped less by individual talent and more by the groups people belong to. He reframes leadership around social norms, group dynamics, and collective context—arguing that leaders often misdiagnose performance problems by focusing on people instead of the group system they operate within.Part Two builds on that foundation with practical guidance for leaders. Fisher explains why teams frequently underperform—not because of effort or ability, but because organizations are designed to reward and manage individuals, not collective work. He introduces the concept of relaunching teams, offering a roadmap for resetting goals, norms, and roles so groups can move from friction to true collaboration. The episode closes with a powerful shift in perspective: sustainable performance improves when leaders stop fixing individuals and start strengthening the group.Episode Highlights• Why teams often perform worse than individuals—and how leaders can     change that.• The 60–30–10 rule that explains what really drives team performance• How to relaunch a struggling or inherited team• The role of shared goals, norms, and “superpowers” in building trust• Moving from me vs. you to us vs. the problemGuest:  Colin M. Fisher, Ph.D. author of the book,The Collective Edge: Unlocking the Secret Power of Groups Host, Chris Comeaux, President / CEO of TELEIOS and author of The Anatomy of Leadership.Teleios Collaborative Network / https://www.teleioscn.org/tcntalkspodcast

Local KC Groups Protest, But Who is Funding Them? | Mundo Clip 1-21-26See omnystudio.com/listener for privacy information.

For me the most illuminating insight into what these laws are actually designed to do came up in an ABC interview with Attorney-General Michelle Rowland on Tuesday. Over and over again throughout the interview Rowland was asked by ABC's David Speers to clarify whether the new laws could see activist groups banned for criticizing Israel and opposing its genocidal atrocities in a way that causes Jewish Australians to feel upset feelings, and she refused to rule out the possibility every single time. Reading by Tim Foley.

Farmers across the country have called for increased federal support for months, citing dire economic conditions. A letter sent to Congress on January 15 signed by 56 prominent agricultural groups warns of further fallout.

Send us a textIn this episode of Anatomy of Leadership, host Chris Comeaux is joined by Colin Fisher, professor, researcher, author, and jazz trumpeter, to explore what decades of research reveal about how groups really work—and why so many teams struggle to reach their potential.Drawing from his book The Collective Edge, Colin challenges the myth of the “lone genius” and reframes leadership as a discipline of design.  Instead of motivating harder or managing individuals more closely, leaders are invited to think like architects—intentionally shaping team size, structure, norms, and psychological safety so collaboration and learning can emerge naturally.This conversation dives into why most teams are too large to function effectively, how hidden norms silently shape behavior, and why harmony is often mistaken for real collaboration.  With practical examples from healthcare, hospice, and other mission-driven environments, the episode offers research-backed insight into building teams that learn, adapt, and perform under pressure.Episode Insights•Why teams are often less than the sum of their parts•How team size and structure impact decision-making•What psychological safety really looks like in practice•Why disagreement is essential for strong teams•How leaders can unlock collective intelligence—not suppress itIf you lead teams, sit in meetings, or want collaboration to actually work, this episode will fundamentally change how you think about leadership and group performance.Subscribe for more conversations on leadership, systems, and human behavior.

This week on Between Us Moms, Hallie and Katie are covering everything moms are actually talking about — from toddler bedtime procrastination and toxic mom group culture and celebrity mom drama (Hilary, Mandy and Ashley -- we're looking at you!) and whether farting in front of your partner really makes your marriage stronger.We kick things off with our Yays & Nays of the Week, including Hallie's gross but honest realization about men that has us questioning everything. Then Katie opens up about a VERY relatable toddler sleep struggle — her child wants her in the crib every single night before falling asleep. Sound familiar? We're talking bedtime stalling tactics like asking for more milk, more water, one more story, or demanding a parent lay with them — and we're sharing realistic bedtime hacks and parenting tips to help if your toddler is fighting sleep. In our Headlines That Made Us Text Each Other, we dive into the toxic mom group conversation sparked by celebrity moms Ashley Tisdale, Hilary Duff, and Mandy Moore. Our hosts have a LOT to say about that viral essay and the drama that has ensued. Katie shares exclusive insider insight after interviewing all three of these celebrity moms multiple times — they also share their opposite takes on Matthew Koma's involvement, and why this topic hit such a nerve for modern moms.We also break down Nikki Bella's viral photo kissing her son on the lips, which sent her comment section into absolute chaos. Is it innocent? Is it weird? Is the internet doing too much? Katie and Hallie share their unfiltered hot takes.And finally in our Mom Algorithm segment … we talk gas.

In this episode of Anatomy of Leadership, host Chris Comeaux is joined by Colin Fisher, professor, researcher, author, and jazz trumpeter, to explore what decades of research reveal about how groups really work—and why so many teams struggle to reach their potential.Drawing from his book The Collective Edge, Colin challenges the myth of the “lone genius” and reframes leadership as a discipline of design.  Instead of motivating harder or managing individuals more closely, leaders are invited to think like architects—intentionally shaping team size, structure, norms, and psychological safety so collaboration and learning can emerge naturally.This conversation dives into why most teams are too large to function effectively, how hidden norms silently shape behavior, and why harmony is often mistaken for real collaboration.  With practical examples from healthcare, hospice, and other mission-driven environments, the episode offers research-backed insight into building teams that learn, adapt, and perform under pressure.Episode Insights •Why teams are often less than the sum of their parts•How team size and structure impact decision-making•What psychological safety really looks like in practice•Why disagreement is essential for strong teams•How leaders can unlock collective intelligence—not suppress itIf you lead teams, sit in meetings, or want collaboration to actually work, this episode will fundamentally change how you think about leadership and group performance.Subscribe for more conversations on leadership, systems, and human behavior.

Text Us Your Feedback! (Likes, Dislikes, Guest/Conversation Recommendations). When co‑host Brandon Clift and his pregnant wife climbed aboard a neighbour's Piper Apache, they expected a relaxing ski trip in West Virginia. Instead, one engine failed on take‑off, forcing their small plane to circle back as gusting winds pushed them toward the trees. With another pilot trailing the plane calmly advising “hold your blue line” over the radio, their pilots managed a safe landing. In this episode, Brandon recalls looking at his wife and wondering whether they were about to orphan their three‑year‑old daughter while denying their unborn baby a chance to live. He explains how that question cracked open his own perfectionism and catalysed a new commitment to “sovereignty” and action."Is this it?"Brandon shares the full story of the incident and, more importantly, what shifted in the weeks that followed. This conversation explores how proximity to death can strip away old narratives and expose what actually matters.Takeaways – Near‑death experiences can act as catalysts for growth, but listeners don't need to flirt with danger to integrate the lessons. The hosts encourage men to:Recognise the opportunities and support networks already in place.Choose empowering meanings for challenging events, leveraging the brain's RAS to find evidence that supports growth.Adopt identity‑based habits by deciding who you want to become and taking consistent action.Prioritise purpose and sovereignty over perfectionism.This episode is not about chasing danger or manufacturing trauma. It is an invitation to look honestly at the places where fear, old stories, and self protection are quietly delaying the life you already know you are meant to live.If you have been waiting for certainty, permission, or the perfect plan, this conversation may be the nudge you did not know you needed.- Atomic Habits by James Clear  BetterHelp: Get 10% Off Your First Month Of Therapy The ManKind Podcast has partnered with Betterhelp to make it easier for listeners to access licensed mental health therapists who can aid them in their mental health journey. Brandon and Boysen stand by this service as they use BetterHelp for their therapy needs.#Sponsorship #AdSupport the showGet up to 48% off Magic Mind with our link:https://magicmind.com/MANKIND50 Subscribe/Rate/Review on iTunes ⭐⭐⭐⭐⭐: >>>HERE

More and more radical groups swarm into Minneapolis to protest ICE and ramp up tensions. Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's episode, Editor in Chief Sarah Wheeler talks with Senior Real Estate Reporter Brooklee Han about the DOJ's continued involvement in real estate commission lawsuits — as well as  their decision to let the Compass-Anywhere deal go through. Related to this episode: DOJ is still keeping a close eye on real estate commission rules WSJ: DOJ leadership halted antitrust review of Compass–Anywhere deal HousingWire | YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ More info about HousingWire To learn more about Trust & Will click here. The HousingWire Daily podcast brings the full picture of the most compelling stories in the housing market reported across HousingWire. Each morning, listen to editor in chief Sarah Wheeler talk to leading industry voices and get a deeper look behind the scenes of the top mortgage and real estate.

Pastor Jordan Hansen explores Jonah 3, focusing on saying "yes" to the mercy of God. This message highlights the God of second chances who offers grace to the undeserving. Discover how the Ninevites responded with repentance and fasting when faced with truth. Experience a deeper understanding of how Jesus is both just and merciful.   Pastor: Jordan Hansen Series: I Said Yes (3) Title: Yes to God's Mercy Verses: Jonah 3:1-10 Date: 2026.01.17+18   LINKS:

Catch the message "Faith Forward: Groups" by Pastor Scott Jones.Following Jesus is not something you do alone. We'll lay the foundation for biblical community and invite people to “get out of a row and into a circle” where they can be in a group to care for one another, pray for one another, and encourage one another to be more like Jesus.

All sin separates us from God. Some sins—pride, envy, wrath, sloth, greed, lust, gluttony—can destroy us. Jesus gives us virtues that overcome these vices.This 8-week series examines the Seven Deadly Sins not to shame, but to reveal our need for grace. Each week shows how these sins infiltrate life, harm relationships, and distance us from God—and how Jesus provides the way out. The final week focuses on virtue and victorious life in Christ.The concept of the "deadly sins" goes all the way back to Aristotle, but the Christian perception originated in the fourth century with a group known as the "desert fathers." These men, seeking freedom from the corruption of the world, committed to a hermitic life in the desert of Africa (mostly Egypt). But when they arrived in the desert, they discovered the corruption had followed them there! Out of this experience came the understanding that sin isn't primarily "out there" but "in here." And today, you and I have 1700 years of experienced shoulders to stand on as we fight these tendencies in our own souls. These men discovered the depth of their own sin in the desert, and in that same place they also discovered that the power of the Gospel could lead them into lives of virtue and victory.Let's listen in…LINKS + RESOURCES FROM THIS EPISODE:• Glittering Vices by Rebecca DeYoung and other recommended reading for this series• Catholic, Orthodox, Protestant• Timothy George: “4 Groups of Sin” 1) immorality 2) idolatry 3) animosity 4) Intemperance• Download the free study guide, complete transcript, and show notes here.• Scripture References: Galatians 5, verses 15-26; Romans 7; Hebrews• Find out more about Covenant Church at ⁠covenantexperience.com

In this episode of 15:14, Kevin Carson, Executive Director of the Biblical Counseling Coalition, is joined by David Peterson, BCC team member and director of the 133 Networking Groups. David reintroduces this vital ministry, shares stories of how God is using these groups, and explains how listeners can join an existing group or even begin a 133 group in their own region. One of the great joys of the Biblical Counseling Coalition is bringing together biblical counselors from a wide variety of backgrounds to cultivate gospel-centered fellowship, encouragement, and collaboration. In this episode of 15:14, we highlight one ministry that does this in a unique and powerful way -  the 133 Networking Groups. This conversation invites counselors into deeper fellowship, reminds us that ministry is not meant to be done alone, and encourages participation in a growing network committed to Christ-centered, Scripture-saturated care. The BCC currently supports 133 Networking Groups around the world, along with two virtual groups. These groups provide meaningful spaces for counselors to encourage one another, share resources, pray together, and grow stronger in their ministry. FROM OUR SPONSOR:  To learn more about an undergraduate degree in biblical counseling, go to BoyceCollege.com/1514. For more information on the Biblical Counseling and Master of Divinity degree in 60 months go to BoyceCollege.com/five. Support 15:14 – A Podcast of the Biblical Counseling Coalition today at biblicalcounselingcoalition.org/donate.

Chris Franjola is here! Chris reviews the movie Is This Thing On? We get into the Golden Globes and it's mistakes. Mel Robbins has competition and her name in Manifesting Mama! We discuss Pete Davidson's glow-up, questionable tattoos, toxic mom groups, Ellen casually buying a $27 million house, Dr. Oz, autistic Barbie, Cher's love life, the Beckham family, Candy Spelling, and whether AI photos are about to steal all our faces. So Juicy So funny! -Discover a softness beyond your wildest dreams with Boll & Branch. Get 15% off your first order plus free shipping at ⁠https://bollandbranch.com/juicyscoop⁠  with code juicyscoop.  -Refresh your wardrobe with Quince. Don't wait. Go to ⁠https://quince.com/juicy⁠  for free shipping on your order and 365-day returns. Now available in Canada, too.  -Get a free can of OLIPOP. Buy any 2 cans of Olipop in store, and we'll pay you back for one. Works on any flavor, any retailer. Go to https://drinkolipop.com/JUICYSCOOP  -Go to https://RO.CO/JUICYSCOOP for your free insurance check to see if your insurance covers GLP-1s for free. Subscribe to my new show Juicy Crimes!: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/juicycrimes⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Stand Up Tickets and info: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://heathermcdonald.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Subscribe to Juicy Scoop with Heather McDonald and get extra juice on Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/JuicyScoopPod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/juicyscoop ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Watch the Juicy Scoop On YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@JuicyScoop⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Shop Juicy Scoop Merch: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://juicyscoopshop.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Me on Social Media: Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/heathermcdonald⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@heathermcdonald⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@HeatherMcDonaldOfficial⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mom groups are supposed to offer support, but what happens when the energy turns judgmental, competitive, or quietly toxic? Inspired by Ashley Tisdale's viral essay about leaving a toxic mom group, Michaela dives into how auras can assist with knowing how to choose the right mom group for you, and when to leave the wrong one. Michaela talks about what your aura needs in this type of community and what problematic moms can look like in aura color. Scott and Michaela read listeners' experiences with tough mom groups and explore how understanding your own aura can help you choose communities that actually support you, instead of drain you. Want to learn more? Enjoy one of our new interactive Aura quizzes: https://knowyouraura.com/aura-quizzes/Listen to this introductory episode to find your Aura color: https://podcasts.apple.com/us/podcast/bonus-every-aura-color-explained/id1477126939?i=1000479357880Send Mystic Michaela some positive energy on Instagram: https://www.instagram.com/mysticmichaela/Explore the Know Your Aura Website : https://knowyouraura.com/Visit Mystic Michaela's Website: https://www.mysticmichaela.com/Join Mystic Michaela's Facebook Group: https://www.facebook.com/groups/2093029197406168/Our Episode Partners: Get 30% off your first 3 subscription orders when you use code KYA at https://www.oneskin.co/KYAGet $30 off your first box - PLUS free Croissants for life - when you go to https://wildgrain.com/KYA to start your subscription today.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's an Emmajority Report Thursday on The Majority Report On today's program: Trump posts to Truth Social, threatening to invoke the Insurrection Act in Minnesota. Minneapolis resident Patty O'Keefe recounts her experiences as a legal observer being arrested, abused, and detained at the Whipple Center in Minneapolis. The Twin Cities Pioneer Press publishes an article about three Native Americans who were rounded up by ICE. Another Native American speaks about his experience being detained by ICE. This attack on Natives highlights the ICE project is about ethnic cleansing and nothing else. Amed Khan, human rights advocate and political activist, joins Emma to discuss what he has witnessed over the past two years in Gaza. Through the Amed Khan Foundation, he has purchased and delivered emergency child nutrition throughout the genocide in Gaza. Molly White publisher of the Citation Needed newsletter joins Emma to talk about 2025 of having been the year of the "Technoligarchy". In the Fun Half: Brandon Sutton and Matt join the program. Candace Owens posits the theory that Charlie Kirk was a time traveler marked from birth. Makes sense. ICE blinds a 21-year-old in his left eye after shooting him with a pepper ball at point blank. Former Secretary of State, Mike Pompeo speaks at a Zionist conversation in Miami where he says he wants to ensure that history books do not write about the "victims in Gaza". All that and more To connect and organize with your local ICE rapid response team visit ICERRT.com The Congress switchboard number is (202) 224-3121. You can use this number to connect with either the U.S. Senate or the House of Representatives. Follow us on TikTok here: https://www.tiktok.com/@majorityreportfm Check us out on Twitch here: https://www.twitch.tv/themajorityreport Find our Rumble stream here: https://rumble.com/user/majorityreport Check out our alt YouTube channel here: https://www.youtube.com/majorityreportlive Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! https://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: https://majority.fm/app Go to https://JustCoffee.coop and use coupon code majority to get 10% off your purchase Check out today's sponsors: SUNSET LAKE: and use the code NEWFLOWER—all one word—to get 30% off their new crop of hemp flower and vape carts at SunsetLakeCBD.com  Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech On Instagram: @MrBryanVokey Check out Matt's show, Left Reckoning, on YouTube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com

To sign up for Open Forum https://www.openforumgolf.com/ Whats up everybody and welcome to another episode of the golf guru show, I am your host, Jason Sutton and I am the Guru,  I am  also the director of instruction at the beautiful Colleton River club in Bluffton, SC where it is my mission to break down high performers in the teaching and coaching business and all fields of study, unpack and tease out what makes them great and successful from daily habits, their continuous growth journey,  to how they help and train with their students. Make sure that you download this episode and hit that purple subscribe button so you don't miss out of future episodes that will be coming your way. All I ask is that you share this podcast on social or with your friends and with other coaches and players that might benefit from the information. After listening to the audio, go check out the video on youtube channel as well. My guest on this episode is Nick Chertock. Nick is an accountant by trade and a 10 handicap golfer so you might be asking yourself, why is Guru having him on the show. I'm glad you asked because Nick has been instrumental in creating several golf instruction and biomechanics facebook groups over the years that have brought hundreds of coaches, biomechanics, trainers and fitness professionals together for debates and discussions. He is also one of the people that runs the biggest teaching summit in the country called "Open Forum" along with Michael Michelides and Chris Como. It started in 2013 and is held on the Tuesday of PGA Show week. I have attended every one of them and it is a can't miss every year for teachers, coaches and golf enthusiasts. You can sign up on the website at openforumgolf.com. Follow Nick at @golfprogress on IG and X. It was great to catch up with Nick as conversation took many twists and turns that were very unexpected. So here is my friend Nick Chertock....enjoy! Learn more about your ad choices. Visit megaphone.fm/adchoices

Hart, Fitzy and Ted take turns selecting the position groups (WR, DBs, etc.) and units (coaching staff, etc.) that they believe will be most impactful in the outcome of the Patriots-Texans playoff game on Sunday.

Listen to this podcast featuring highlights from our expert roundtable discussion to learn about the most pressing issues in pediatric influenza vaccines, including current vaccine technologies, recent vaccine uptake and epidemiologic trends, and how to discuss the vast benefits of timely vaccination in pediatric patients with their parents and caregivers. Topics covered include:Groups at High Risk for ComplicationsGuideline Recommendations for Influenza VaccinationAvailable Seasonal Flu Vaccine Formulations and Their CharacteristicsPractical Considerations for Selecting Pediatric Influenza VaccinesUptake of Influenza Vaccines in Children: Reversing the TrendsPresenters:Ravi Jhaveri, MD, FIDSA, FPIDS, FAAPDivision HeadPediatric Infectious DiseasesAnn & Robert H. Lurie Children's Hospital of ChicagoProfessor of PediatricsNorthwestern University Feinberg School of MedicineChicago, IllinoisTina Q. Tan, MD, FAAP, FIDSA, FPIDSProfessor of PediatricsFeinberg School of Medicine of Northwestern UniversityPediatric Infectious Diseases AttendingMedical Director, International Adoptee ClinicPresident, Lurie Medical/Dental StaffAnn & Robert H. Lurie Children's Hospital of ChicagoChicago, IllinoisJennifer M. Walsh, DNP, CPNP-PC, CNECertified Pediatric Nurse Practitioner, Primary CareAssistant ProfessorGeorge Washington UniversitySchool of NursingWashington, DCLink to full program: https://bit.ly/45UVzy6Get access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Is the era of the massive Indian Army over? In this episode of In Our Defence, Dev Goswami and Sandeep Unnithan decode the Indian Army's roadmap for force restructuring, a project that has been in the works for several years. The two answer the big questions: -Why is the Army desperate to "cut the flab"? -What exactly are Integrated Battle Groups (IBGs), and how do they change the way India fights wars? The episode also features a deep dive into the Army's massive push for drones and whether tech is finally replacing boots on the ground. Finally, Dev and Sandeep imagine what the future Indian Army infantry soldier will look like and why the science fiction movies of the past years may not be so far off the mark on this aspect. Tune in! Produced by Taniya Dutta Sound mixed by Aman Pal

Live from AIM Expo 2026, Tom and Cindy Hicks share how they built Southern California Motorcycles into the #1 Triumph dealer in North America—and what it took to successfully exit after 25 years.They break down the small operational changes that drove big financial gains, why labor rate increases rarely impact customers, and how data, discipline, and 20 Groups shaped long-term success. A must-listen for dealers focused on profitability, sustainability, and planning their next chapter.

Awards season has begun, and the Irish are back!To support the podcast and access bonus episodes, join the community on Patreon here. Hosted on Acast. See acast.com/privacy for more information.

If you were on social media late last week you may have noticed a flurry of announcements, statements, and posts from beef and cattle groups addressing misinformation circulating about traceability regulation changes for livestock. "Beef Farmers of Ontario (BFO) is aware of questions and discussion regarding the proposed federal livestock traceability regulations and their anticipated... Read More

Public anger continues to build after the fatal shooting of Renee Nicole Good by an ICE agent in Minneapolis, with many women leading protests and demanding accountability. Commentary from Joy Reid intensified the conversation after she said, “This woman was part of a group of people who they train to try to be ICE interrupters… They try to observe what ICE is doing, film them, and try to use their white privilege, to be honest — they’re mainly white people. As Black people, we can’t put our bodies on the line, because cops will shoot us.” Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Everyone's favourite handball nerd Rasmus Boysen joins us for our second EHF EURO 2026 preview pod, featuring Groups B, C and E. We delve into the championship's host nations, fan favourites Portugal and Netherlands and compare the two perennial top contenders in Denmark and France. The full extended episode, plus bonus episodes throughout the tournament, can be enjoyed on patreon.com/handballhour

Text Us Your Feedback! (Likes, Dislikes, Guest/Conversation Recommendations). What if the violence we fear most isn't just about ideology or mental health—but about how we teach boys to be men?In this powerful conversation, Boysen sits down with Dr. Cynthia Miller-Idriss—renowned extremism researcher, advisor to Congress and the UN, and author of Man Up: The New Misogyny and the Rise of Violent Extremism. Together, they explore the often-overlooked role of misogyny as a root cause of radicalization, mass shootings, and political violence.But this episode isn't just about warning signs—it's about reckoning, responsibility, and reclaiming connection.Dr. Miller-Idriss brings research, clarity, and compassion to one of the most urgent conversations of our time.

How can governments incentivize couples to have more babies? What do you do when your fun mom group turns exclusive and "toxic"? And, in case you missed it, a "Here for the Comments" conversation about all the hate Katy got on her post about overturning Obergefell.

Just weeks into the new year, the Trump administration has rolled out a campaign across departments that draws on images and ideas borrowed from right-wing and white nationalist circles. Liz Landers reports on what some of these images and posts mean, and Amna Nawaz discusses more with Cynthia Miller-Idriss of the Polarization and Extremism Research Innovation Lab at American University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Jodi's experience with toxic mom groups and how she handled it. #family #momlife #toxicSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott talks about social media complaint groups, which include people complaining about a certain coffee/donut chain, people breaking into cars and not picking up after your dog poops.

Jordan Hansen continues the Jonah series with a focus on saying "yes" to the answer from God. Even in hopeless places, prayer remains fertile ground for hope. This study examines the prayer of Jonah from the fish and the declaration that salvation comes from the Lord alone. Discover how God brings purpose to pain and redemption to difficult circumstances.   Pastor: Jordan Hansen Series: I Said Yes (2) Title: Yes to God's Answer Date: 2026.01.10+11   LINKS:

Just weeks into the new year, the Trump administration has rolled out a campaign across departments that draws on images and ideas borrowed from right-wing and white nationalist circles. Liz Landers reports on what some of these images and posts mean, and Amna Nawaz discusses more with Cynthia Miller-Idriss of the Polarization and Extremism Research Innovation Lab at American University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Unlocked Patreon episode. Support Ordinary Unhappiness on Patreon to get access to all the exclusive episodes. patreon.com/OrdinaryUnhappinessHappy New Year! We're off this week taking a belated holiday rest. But as a complement to our miniseries on projective identification with Brian Ngo-Smith, we're unlocking this episode featuring another returning audience favorite: Lily Scherlis. Lily leads Abby and Dan on a deep dive into the psychoanalytic study of groups, from its history and roots in Wilfred Bion's theories to her own personal experiences and reportage. Like our recent episodes with Brian, the conversation expands to thinking about groups more broadly, and into the arena of contemporary politics in general and the challenges of leftist solidarity specifically. -Abby and Dan sit down with writer and performance artist Lily Scherlis to talk about her new essay for n+1, “Experiences in Groups” (a title that does homage to Wilfred Bion's influential 1961 book of the same name). They discuss Lily's experience at the 2024 Tavistock conference, the meaning of “group relations,” and the fantasies it can generate for those committed to leftist politics, before turning to their own experiences in groups and Bion's influence on each of their lives.  Lily Scherlis, “Experiences in Groups”: https://www.nplusonemag.com/issue-51/essays/experiences-in-groups/Wilfred Bion, Experiences in Groups: https://bookshop.org/p/books/experiences-in-groups-and-other-papers-w-r-bion/0d24f44dde25497d?ean=9780415040204&next=t&Nov 14th event of interest to NYC listeners: “Group as Form; Deep Study Session with Groups Group” (registration and fee required): https://www.poetryproject.org/events/group-as-form-deep-study-session-with-groups-group?page=1Our previous episode with Lily, “From Boundaries to Attachment: The Uses and Abuses of Pop Psychology”: https://ordinaryunhappiness.buzzsprout.com/2131830/episodes/17036523-98-from-boundaries-to-attachment-the-uses-and-abuses-of-pop-psychology-feat-lily-scherlisOur previous episode on Bion's Experiences in Groups with Christine Smallwood: “From Parties to Projective Identification: Why Is Group Life So Hard?”: https://ordinaryunhappiness.buzzsprout.com/2131830/episodes/13002667-12-from-parties-to-projective-identification-why-is-group-life-so-hard-feat-christine-smallwood

Federal officials have reduced the number of vaccines recommended for children. Some state medical groups say they will continue to follow the old guidelines. Parents will need to talk to their doctor to get the shots that are no longer recommended for all children.

We all know how important a mom group can be for your mental health and support, especially when you don't have family around. Mom groups are supposed to be your safe space… until they leave you out in the cold. We're talking about Ashley Tisdale feeling excluded from a celeb mom group that included none other than Hilary Duff. If you've ever found yourself on the outside of a group thinking, What did I do? What's wrong with me? Follow that up with: Why would I even want to be around people who make me feel like this? We want to hear from you! Weigh in and tell us your thoughts on the mom group controversy!Want our podcasts sent straight to your phone? Text us the word "Podcast" to +1 (917) 540-8715 and we'll text you the new episodes when they're released!Tune in for new Cat & Nat Unfiltered episodes every Monday, Tuesday, Thursday and Friday!Follow @catandnatunfiltered on Instagram: https://instagram.com/catandnatunfilteredOur new book "Mom Secrets" is now available! Head to www.catandnat.ca/book to grab your autographed copy! Come see us LIVE on tour!! To see a full list of cities and dates, go to https://catandnattour.com.Are you a parent that is struggling understanding the online world, setting healthy screen-time limits, or navigating harmful online content? Purchase screen sense for $24.99 & unlock Cat & Nat's ultimate guide to parenting in the digital age. Go to https://www.thecommonparent.com/screen-sense-ebookFollow our parenting platform - The Common Parent - over on Instagram: https://instagram.com/thecommonparentMake sure you subscribe to our YouTube channel: https://bitly.com/catnatyoutubeCheck out our Amazon Lives here: https://bitly.com/catnatamazonliveOrder TAYLIVI here: https://taylivi.comGet personalized videos from us on Cameo: https://cameo.com/catandnatCome hang with us over on https://instagram.com/catandnat all day long.And follow us on https://tiktok.com/@catandnatofficial! Hosted on Acast. See acast.com/privacy for more information.

This segment of the Omni Talk Retail Fast Five, sponsored by the A&M Consumer and Retail Group, Mirakl, Ocampo Capital, Infios, Quorso, and Veloq, features Chris and Anne closing out the show with rapid-fire takes on the lighter (and weirder) side of retail and culture. The conversation jumps from LEGO's smart brick ambitions to the rise of toxic mom groups online, plus the internet's obsession with five-gallon popcorn buckets. Chris and Anne also weigh in on whether the Stranger Things finale deserves a do-over because no Lightning Round is complete without a strong pop culture opinion. ⏩ Tune in for the full episode here: https://youtu.be/j0UulTYE5_8 #LightningRound #RetailFastFive #OmniTalk #RetailCulture #PopCulture #ConsumerTrends #StrangerThings #LEGO

Welcome back to The Snack – a lighter serving of Girls Gotta Eat. This week, we're talking about: Timothée Chalamet's acceptance speech about Kylie  Best/funniest red carpet look for the Critics Choice Awards Movie reviews: Marty Supreme, Housemaid, Is This Thing On?  TV reviews: Emily in Paris, Stranger Things, and a deep dive on Heated Rivalry Ashley Tisdale broke up with her celeb mom group  Headlines: Tom Brady and Alix Earle, Zach Bryan marries his ex's doppelganger, NYC retires the MetroCard Follow us on Instagram @girlsgottaeatpodcast, Ashley @ashhess, and Rayna @rayna.greenberg. Visit girlsgottaeat.com for more. Thank you to our partners this week: Just Thrive: Get 20% off at justthrivehealth.com with promo code GGE. Skims: Shop our favorite bras and underwear at https://skims.com.

In the early centuries of Church history as well as in our day, many cults and false teachings have denied either the full deity or the full humanity of the Lord Jesus Christ. Groups such as the Arians taught that Jesus was merely God's highest created being, while the Gnostics believed that he was divine and only appeared to be human. What does the Bible teach about the deity and the humanity of Jesus Christ? Find out on Dr. Barnhouse and the Bible. To support this ministry financially, visit: https://www.oneplace.com/donate/791/29?v=20251111

Terry Real is a therapist and best-selling author expert on male emotional health and how men can build the skills for healthy relating to others: in relationships, work, friendships and to themselves. We discuss how mixed and ever-changing messages about what masculinity is are impacting the mental and physical health of men and boys. Terry explains how learning the skill of "relationality" leads to improvements in all aspects of boys' and men's lives and shares practical tools for how to do that. We also discuss the essential role of having a close male community to build confidence and self-esteem. This conversation offers actionable guidance for boys, men and women seeking to build healthier relationships with themselves and others. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman David: https://davidprotein.com/huberman Function: https://functionhealth.com/huberman Waking Up: https://wakingup.com/huberman Timestamps (00:00:00) Terry Real (00:02:53) Men & Masculinity, Political vs Psychological Patriarchy, Feminism (00:07:39) Stoicism, Vulnerability, Traditional Masculinity, Emotions (00:10:50) Sponsors: BetterHelp & David (00:13:14) Masculinity Across Decades, Giving; Gratification vs Relational Joy (00:21:54) Healthy Emotional Expression, Connection & Vulnerability; Self-Esteem (00:31:17) Feeling Emotions, Tools: Asking For Help; Fights & "What Do You Need?" (00:35:10) Self-Esteem & Relationship Accountability; Criticism, Redefining Strength (00:40:47) Sponsor: AG1 (00:42:32) Healthy Criticism, Tool: Women & Articulating Needs (00:50:21) Childlike Behavior, Wise Adult & Trauma, Tool: Relational Mindfulness (00:58:11) Tool: Responsible Distance Taking; Self-Interest; Relationship "Biosphere" (01:08:14) Alcohol, Men & Friends, Loneliness, Men's Retreat (01:17:51) Fraternities, Men's Groups, Tool: Relationship vs Individual Support (01:25:39) Sponsor: Function (01:27:27) Lack of Male Friends, Hiking, Community, Teaching Young Men (01:36:11) Cannabis, Alcohol, Young Men & Purpose, Flexibility & Manliness (01:40:40) Work, Life Purpose & Men; Skillful Warriors (01:45:01) Absent Fathers; Early Childhood & Proper Nurturing; Caretaking (01:53:24) Sponsor: Waking Up (01:54:47) Women & Speaking Relationally, Objectivity Battle (01:59:02) Addiction & Disconnection, 12-Step Meetings & Fellowship (02:08:04) Pornography, Internet, Intensity vs Intimacy; Optimization (02:11:57) Tool: Families & Hanging Out; Relational Joy; Relational Recovery (02:22:29) Giving Criticism, Tools: Make Requests; Feedback Wheel (02:28:21) Gratitude, Aging; Skillful Fighting in Relationship & Repair (02:34:17) Men & Self-Esteem, Mentors, Tool: Inner Dialogue without Harshness (02:44:00) Y Chromosome, Wholeness (02:48:00) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices